SCIEX Zeno SWATH DIA for the ZenoTOF 7600 system

SCIEX has launched Zeno SWATH DIA, a useful tool in biomarker discovery and translation workflows. Available on the company’s ZenoTOF 7600 system, the process provides a digital record of a sample that can enable researchers to discover more potential biomarkers to be used in the development of clinical tests and in the discovery of new therapies.

By combining the sensitivity and robustness of the ZenoTOF 7600 system and the high dynamic range of Zeno SWATH DIA, researchers should be able to routinely quantify more cell and plasma proteins than previously possible with SWATH approaches. The ability to quantify large numbers of lesser abundant proteins that were previously undetectable means that more potential biomarkers can be taken through to verification.

To enable translational research, this performance can be delivered at large scale. Runtimes can be shortened to as little as 5 min with minimal compromise in proteome coverage. Large population-scale proteomic studies can be achieved in a matter of weeks, without compromising on the depth of information obtained. This means the potential for the development of clinical tests for early detection of disease is increased.

The sensitivity of the process also enables large numbers of proteins to be quantified from sample loadings up to 10-fold lower than previous SWATH approaches, the company says. Lower sample loads mean reduced cost per sample in large-scale studies and minimised sample consumption from in vivo models during drug development. Additionally, it creates opportunities for large population-scale sample collection methods such as patient-centric microsampling devices.